Weiss Law reminds shareholders of FSTX, ZEN, RDUS and EPZM of its ongoing investigations

NEW YORK, July 6, 2022 /PRNewswire/ —

If you hold shares in any of the companies listed above and
want to discuss our surveys or have questions about
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss’ law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]

F-star Therapeutics, Inc. (NASDAQ:FSTX)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of F-star Therapeutics, Inc. (NASDAQ: FSTX), in connection with the proposed acquisition of FSTX by invoX Pharma via a tender offer. Under the terms of the merger agreement, FSTX shareholders will receive $7.12 in cash for each FSTX common share held. If you own FSTX shares and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/fstx

Zendesk, Inc. (NYSE:ZEN)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Zendesk, Inc. (NYSE: ZEN), in connection with the proposed acquisition of ZEN by investment firms Permira and Hellman & Friedman LLC. Under the terms of the merger agreement, ZEN shareholders will receive $77.50 in cash for each ZEN ordinary share held. If you own ZEN stock and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/zen

Radius Health, Inc. (NASDAQ:RDUS)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Radius Health, Inc. (NASDAQ: RDUS), in connection with the proposed acquisition of RDUS by Gurnet Point Capital and Patient Square Capital via a tender offer. Under the terms of the merger agreement, RDUS shareholders will receive $10.00 per share plus a contingent value right (CVR) of $1.00 per share payable on TYMLOS® net sales reaching $300 million during any period of 12 consecutive months before December 31, 2025. If you own RDUS shares and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/rdus

Epizyme, Inc. (NASDAQ:EPZM)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Epizyme, Inc. (NASDAQ: EPZM), in connection with the proposed acquisition of EPZM by Ipsen SA via a public tender offer. Under the terms of the merger agreement, EPZM shareholders will receive $1.45 in cash, plus a contingent value right (CVR) for each EPZM ordinary share held. If you own EPZM shares and would like to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/epzm

SOURCE Weiss’ Law

Comments are closed.